Health Trials

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases

3

Review clinical trials related to Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Caris Chromoseq Data Collection

The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis of the study is that Caris Chromoseq compares favorably to conventional cytogenetics, FISH, and NGS analysis in terms of risk stratification capabilities, ease of use, and turnaround time.

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Caris Science, Inc.Updated: Jul 2, 2026Locations: 1
Eligibility criteria

Stated willingness to comply with all study procedures and availability for the... [+4]

Patient for whom Caris Chromoseq is not being ordered [+2]

Read more
Status: Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Participants needed: 99,999
Trial details
Biological sex: AllType: ObservationalSponsor: Center for International Blood and Marrow Transplant ResearchUpdated: Jun 4, 2026Locations: 142
Eligibility criteria

Disorders affecting the hematopoietic system that are inherited, acquired, or re... [+2]

Patients who are receiving only licensed CBUs [+3]

Read more
Status: Not yet recruiting

Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms

To learn if imetelstat can help to control MDS/MPNs.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 24, 2026Locations: 1
Eligibility criteria

Age ≥18 years as MF and CMML are very rare diseases in the pediatric population. [+16]

Participants who are currently receiving treatment for a malignancy (not includi... [+8]

Read more